Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma

Arya, Malvika; Duker, Jay S.

doi:10.1186/s40942-018-0121-3

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports involving the use of palbociclib for metastatic breast carcinoma have been in conjunction with and/or following non-response to other treatment modalities [22][23][24][25]. Ours is the first report wherein palbociclib has been used as the first-line palliative chemotherapy and helped in regression of choroidal metastasis.…”

Section: Discussionmentioning

confidence: 88%

“…The primary tumor was Stage IIIA T3N1M0 infiltrating duct carcinoma of the breast with ER positive, PR positive, HER2 negative expressivity. The primary malignancy was treated with surgical resection and adjuvant chemoradiation, followed by hormone therapy with numerous agents (including palbociclib) in combination with kinase inhibitors for ER resistance [23]. In another case report of ER positive, PR positive, HER2 negative breast carcinoma in a 38-year-old woman treated with right mastectomy and axillary lymph node dissection, followed by four cycles of docetaxel and cyclophosphamide and adjuvant radiation, the patient developed multiple bone metastases in addition to mediastinal lymphadenopathy, two years after the primary diagnosis [24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Regression of choroidal metastasis from breast carcinoma with palbociclib

Parakh¹,

Das²,

Maheshwari³

et al. 2022

Int J Retin Vitr

View full text Add to dashboard Cite

Background Uveal metastasis is reported to be the most common intraocular malignancy. The most common site of origin of ocular metastases in females is the breast. In some cases, uveal metastatic lesions respond to systemic chemotherapy. We report a case of a patient who developed choroidal metastasis, while on endocrine therapy with selective estrogen receptor modulator (SERM), tamoxifen, for estrogen receptor (ER) positive, progesterone receptor (PR) positive and (human epidermal growth factor receptor 2) HER2 negative primary breast carcinoma, which then regressed following systemic chemotherapy with palbociclib. Case description An 83-year-old female, with a history of modified radical mastectomy, chemotherapy and radiation therapy for infiltrating duct carcinoma of the breast, presented with a choroidal metastatic lesion in the left eye along with liver and lung metastases, 3 years after the primary carcinoma was treated. At the time of presentation, she was on tamoxifen. The choroidal tumor showed regression after the introduction of palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Conclusion This report highlights the use of palbociclib, in the palliative treatment of choroidal metastasis from primary breast cancer. The use of chemotherapy for choroidal metastasis can help avoid external beam radiation therapy and its concurrent side effects. Although there are a few reports involving the use of palbociclib for metastatic breast carcinoma, all of those have been in conjunction with and/or following non-response to other treatment modalities. Ours is the first report wherein palbociclib has been used as the first-line palliative chemotherapy and helped in regression of choroidal metastasis.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Regression of choroidal metastasis from breast carcinoma with palbociclib

Parakh¹,

Das²,

Maheshwari³

et al. 2022

Int J Retin Vitr

View full text Add to dashboard Cite

show abstract

Rare sites of breast cancer metastasis: a review

Micco¹,

Santurro²,

Gasparri³

et al. 2019

Transl. Cancer Res.

View full text Add to dashboard Cite

Breast cancer (BC) metastasis accounts for the majority of deaths from BC. The rate of metastasis to uncommon sites is on the rise due to the more effective therapy prolonging survival and to the early detection on imaging. The evaluation of patient-reported symptoms is essential in detecting a recurrence as early as possible, which may impact survival. Hence, the knowledge of even the rare sites of BC metastasis is of paramount importance for the clinical interpretation of new symptoms in BC survivors. The term “unusual metastasis” defines a systemic failure with a frequency of ≤1% at each site and according to this unusual metastasis involve the central nervous system, secretory/endocrine organs and glands, internal organs and structures, and gynecological organs. The literature search was performed using the electronic database PubMed up to December 2018, with the following key words: {[rare(Title/Abstract)] OR [ unusual (Title/Abstract)] OR [ unconventional (Title/Abstract)]} AND {[ metastases (Title/Abstract)] OR [ metastasis (Title/Abstract)]} AND {[ breast (Title/Abstract)]} AND {[ cancer (Title/Abstract)] OR [ tumor (Title/Abstract)] OR [ tumour (Title/Abstract)] OR [neoplasm(Title/Abstract)]}. The search was limited to papers in English language. Of the 3,086 papers found, 757 were excluded as reporting animal models, 378 were not in English language, 1 was a duplicate of the same research, 1,414 did not report on BC metastases, 108 were previous review reviews on BC or tumour to tumour metastases; 428 papers were included in this review. Despite the improvements in BC management, most deaths from cancer result from metastases that are resistant to conventional therapies. In general, it is uncommon to find isolated rare metastases, the vast majority of these develops together with metastases in other sites, thus highlighting a worsening systemic disease. However, the early detection of even rare metastases represents the only chance to control the disease and prolong survival while waiting for the development of more effective systemic therapies.

show abstract

Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma

Cited by 2 publications

References 30 publications

Regression of choroidal metastasis from breast carcinoma with palbociclib

Regression of choroidal metastasis from breast carcinoma with palbociclib

Rare sites of breast cancer metastasis: a review

Contact Info

Product

Resources

About